The combined use of antimullerian hormone and age to predict the ovarian response to controlled ovarian hyperstimulation in poor responders: A novel approach

ABSTRACT

CONTEXT: Reduced ovarian response to stimulation represents one of the most intractable problems in infertility treatment. As failed cycle can cause considerable amount of emotional and economical loss, there are various attempts made to predict ovarian response. AIMS: To evaluate different factors influencing outcome of assisted reproduction in women with predicted reduced response (antimullerian hormone between 1 and 5 pmol/L) and to develop a model using of AMH and age to predict the number of oocytes in poor responders. SETTINGS AND DESIGN: Retrospective study in a teaching hospital. MATERIALS AND METHODS: We analyzed 85 cycles (57 women) with predicted reduced response with serum AMH value between 1 and 5 pmol/L. Standard ovarian stimulation protocol was used. Primary outcome measures were clinical pregnancy rates and oocytes retrieved. STATISTICAL ANALYSIS USED: Data were analyzed using Microsoft excel and MetlabR software. RESULTS: Clinical pregnancy rate/ET was 20.33%, in this group. AMH and age was analyzed using linear regression model which produced an equation to give predicted oocyte count if AMH and age are known. (Oocytes = age × (-β) + Serum AMH × α) (Constant β=0.0102 and α = 1.0407). CONCLUSIONS: Combined use of serum AMH and age to predict ovarian response within reduced responder group should be further evaluated. For first time, we suggested combining both factors to predict ovarian response using a simple equation which allow developing tailored strategy.

INTRODUCTION

Failed-assisted conception cycle causes considerable amount of emotional and economical loss. There are various attempts made to predict reduced response. Evidence has shown convincingly that poor ovarian response is a first sign of ovarian ageing. The Bologna criteria define the poor response as presence of two or more features (i) advanced maternal age or any other risk factor for poor ovarian response; (ii) a previous poor ovarian response; and (iii) an abnormal ovarian reserve test. Two episodes of poor ovarian response after maximal stimulation deemed sufficient to define a patient as poor responder in the absence of other criteria. Ovarian ageing can occur independently of chronological age. AMH suggested being a better marker of ovarian responsiveness, as it reflects the size of the larger resting pool of prefollicle-stimulating hormone (FSH)-dependent follicles. AMH is a more direct and independent measure of the growing preantral and antral follicular pool. Thus age and serum AMH are the most successful predictors of reduced ovarian response. Our aim was to evaluate the role of age and AMH influencing outcome of assisted reproduction in women with predicted reduced response (AMH between 1 and 5 pmol/L) and to develop a model using of AMH and age together to predict the number of oocytes in poor responders. Such model will help clinicians to predict the response and design appropriate protocol. It will also help in patient counselling and advice on alternative management options.
MATERIALS AND METHODS

We have analyzed 85 cycles undergoing controlled ovarian stimulation for IVF or ICSI cycle. These women were treated for either primary or secondary infertility at teaching hospital. All women included were predicted reduced responders with serum AMH value between 1 and 5 pmol/L. We defined reduced responders based on AMH level between 1 and 15 pmol/L based on previous study by. We there was no age cut off. Population was from different ethic background. We have excluded all cases with AMH 5 pmol/L and above as they proved to have normal response and different strategies were used in these cases. We have excluded women with AMH of less than 1 pmol/L, as they demonstrated to have maximum cycle cancellation and no pregnancy occurred in this group. Ovarian stimulation was performed with exogenous gonadotropins initiated on the third or forth cycle day in the form of either Menogon (Ferring Pharmaceuticals, Langley, UK) or Gonal-F (Sero, Feltham, UK). The starting daily dose of FSH was either 225 or 300 IU each day. Ovarian follicular responses were monitored with serum E2 concentrations and transvaginal ultrasound assessment of follicular growth. The GnRH antagonist Cetrotide 0.25 mg/day s.c. (Merck Sero, Feltham, U.K.) or Ganirelix was commenced on days 4-7 if serum E2 exceeded 200 pg/mL. Follicular responses were monitored with serum E2 and transvaginal ultrasound assessment of follicular growth. Ovulation was induced with 6500 IU HCG (Ovitrelle, Sero, Feltham, UK), provided that three follicles were 17 mm in diameter and serum E2 was 200 pg/mL. Trans-vaginal oocyte retrieval was performed under ultrasound guidance 38 h after HCG administration and the number of oocytes retrieved were recorded. Women were either offered IVF-ET or ICSI-ET. The study analysis includes only fresh cycles.

Primary outcome studied was clinical pregnancy rates and secondary outcomes were positive pregnancy rate, oocytes retrieved, and cancellation rate, duration of stimulation, and FSH drug consumption.

The AMH assay was performed in batches one month before treatment cycle using the enzyme-linked immunosorbent assay provided by DSL in study period 2011 (Webster, Texas, USA), with values presented as pmol/L (conversion factor to pg/mL: 1 ng/mL = 7.143). The Reduced responders are defined as predicted with low serum AMH (serum AMH between 1 and 5 pmol/L) and cycle cancellation is defined as less than two matured sized follicles after 2 weeks of stimulation with maximum dose of gonadotropins. Embryo cryopreservation was done with more than one high grade embryo remained after fresh embryo transfer. Data were analyzed using Microsoft excel and MetlabR software. The factors influencing outcome of assisted conception were analysed using linear regression model. A simple matrix formula was derived to calculate predictive response when these factors are known.

RESULTS

The baseline demographic characteristics and outcome are shown in Table 1. The AMH level was ranging from 1.1 to 4.9 as per inclusion criteria. Among 44 eggs retrieved, two failed to fertilize in IVF cycle. A total of 29 (34.1%) cycles were treated by ICSI. Thus, fertilization rate was 91.6% in ICSI cycles. Duration of stimulation was from 4-14 days and from 675 IU to 5100 IU FSH was used. Out of 85 cycles started, eight (9.41%) were cancelled due to poor response. A total of 59 embryos were transferred; two embryos were frozen along with ET in those women. All cancelled cycles are shown in Table 2. Clinical pregnancy was achieved in 12 cases. Characteristics are discussed in Table 3.

Thus, there was no significant difference between these groups. Lower AMH value showed trend toward cancellation and higher AMH value showed trend toward clinical pregnancy in this group. We have analyzed age and AMH, using linear regression model.

The factors Age and AMH were put in linear regression model to produce a solution.

Table 1: Demographic characters

| Procedure       | Number of patients cycles | Age at stimulation (years) | BMI (kg/m²) | AMH (pmol/L) | Procedure | IVF (%) | ICSI (%) | Length of stimulation (days) | Total dose (IU) | Canceled cycles ** | Number of oocytes | Number of embryos transferred | Normal fertilization rate % | IVF (%) | ICSI (%) |
|-----------------|---------------------------|---------------------------|-------------|--------------|-----------|---------|---------|-------------------------------|----------------|-------------------|------------------|-----------------------------|---------------------|---------|---------|
|                 | 85                        | 39 (31-46)                | 24.7±4.6    | 2.9 (1.1-4.9)|           | 56 (65.9)| 29 (34.1)| 10 (4-14)                      | 2100 (675-5100) | 8 (9.41%)         | 3 (0-15)        | 59                          | 37 (94.8)          | 22 (91.6) |
| IVF (%)         |                           |                           |             |              | Procedure |         |         |                               |                 |                   |                 |                             |                     |         |         |
| ICSI (%)        |                           |                           |             |              | Procedure |         |         |                               |                 |                   |                 |                             |                     |         |         |
| No transfer     |                           |                           |             |              | Procedure | 26 (30.5%)| 42 (49.4%)| 5 (20%)                        |                 |                   |                 |                             |                     |         |         |
| Positive pregnancy test |                 |                           |             |              | Procedure | 17 (20%)  | 12 (14.1%) | 6 (16%)                        |                 |                   |                 |                             |                     |         |         |
| Clinical pregnancy |                       |                           |             |              | Procedure | 16%      | 20.33%  | 14.11%                        |                 |                   |                 |                             |                     |         |         |
| Clinical pregnancy per OR |                 |                           |             |              | Procedure | 20.33%  | 14.11%  |                               |                 |                   |                 |                             |                     |         |         |
| Positive pregnancy test |                 |                           |             |              | Procedure | 20.33%  | 14.11%  |                               |                 |                   |                 |                             |                     |         |         |
| Clinical pregnancy per OR |                 |                           |             |              | Procedure | 20.33%  | 14.11%  |                               |                 |                   |                 |                             |                     |         |         |
| Clinical pregnancy per cycle |             |                           |             |              | Procedure | 20.33%  | 14.11%  |                               |                 |                   |                 |                             |                     |         |         |

Values are expressed as median (interquartile range) or mean±standard deviation

**Percentage per cycle started, (n=85). aIncludes women with cancelled cycle; no eggs or failed fertilisation; bIncludes clinical and biochemical pregnancy; AMH=Antimullerian hormone; BMI=Body mass index; ET=Embryo transfer; IU=International units; ICSI=Intracytoplasmic sperm injection; IVF= In vitro fertilization; OR=Odds ratio.
Table 2: Cancelled cycle and all cycles characteristics

| Characteristics     | All       | Cancelled cycles |
|---------------------|-----------|-----------------|
| Total               | 85        | 8               |
| Age                 | 39 (31-46)| 39.9 (35-45)    |
| BMI                 | 24.7±4.6  | 25.9±4.6        |
| AMh                 | 2.9 (1.1-4.9)| 2.2 (1.1-3.3)   |
| Total dose of FSH   | 2100 (675-5100)| 1162.5 (675-4200)|
| Duration of FSH     | 10 (4-14) | 7.5 (7-10)      |

BMI=Body mass index; FSH=Follicle-stimulating hormone

Table 3: Clinical pregnancy and all cycle characteristics

| Characteristics     | All       | Clinical pregnancy |
|---------------------|-----------|-------------------|
| Total               | 85        | 12                |
| Age                 | 39 (31-46)| 37 (35-39)       |
| BMI                 | 24.7±4.6  | 24.5±6           |
| AMH                 | 2.9 (1.1-4.9)| 3.15 (1.2-4.7)   |
| Total dose of FSH   | 2100 (675-5100)| 2287.5 (1350-3600)|
| Duration of FSH     | 10 (4-14) | 10 (8-14)        |
| Number of oocyte retrieved | 3 (0-15) | 4 (2-8)          |

AMH=Antimullerian hormone; BMI=Body mass index; FSH=Follicle-stimulating hormone

Age is always labelled as significant factor affecting fertility but biological aging and ovarian aging are not always same. Various attempts to develop ideal predictive test for ovarian reserve were failed. At same time, AMH emerged as a promising option for predicting both oocyte number and quality. AMH showed definitive advantages over other bio markers. It has linear relationship with age. Previous studies clearly established linear relationship between AMH and oocyte yield using AMH and age to develop a linear regression model for oocyte yield is a justified approach based on past evidence. The accuracy of multivariate models for the prediction of ovarian reserve and pregnancy in women undergoing IVF compared with the antral follicle count (AFC) as single test was reviewed by Verhagen et al. He reviewed age + FSH, age + inhibin B, age + AFC and different combinations for predictive model. He concluded the use of more than one single test for the assessment of ovarian reserve cannot be supported. Thus, the models incorporating inhibin B, FSH, ovarian volume, clomiphene challenge test, and so on failed to deliver successful prediction. Further evidence is required to support the multivariate model of AMH and age to predict ovarian response.

Other factors like body mass index, procedure, previous pregnancy, and duration of pregnancy were analyzed but failed to establish any significant relationship. There are various factors suggested to be significant predictors of clinical pregnancy such as age, serum E (2) concentration on the day of hCG administration, embryo quality, and number of embryos transferred sperm motility and ICSI operator. It is practically impossible to establish relationship between all factors at a time. Hence, we considered most significant
ACKNOWLEDGMENT

I would like to acknowledge Prof. Richard Fleming, University of Glasgow United Kingdom, for his constant help and guidance despite of busy schedule, he helped me from the conception of the idea to the finishing this project successfully.

REFERENCES

1. Nelson SM, Messow MC, Wallace AM, Fleming R, McConnachie A. Nomogram for the decline in serum antimullerian hormone: A population study of 9,601 infertility patients. Fertil Steril 2011;95:736-41.e1-3.
2. Sallam HN, Ezzeldin F, Agameya AF, Abdel-Rahman AF, El-Garem Y. The definition of ‘poor response’: Bologna criteria. Hum Reprod 2012;27:626-7.
3. Akande VA, Fleming CF, Hunt LP, Keay SD, Jenkins JM. Biological versus chronological ageing of oocytes, distinguishable by raised FSH levels in relation to the success of IVF treatment. Hum Reprod 2002;17:2003-8.
4. Fleming R, Deshpande N, Trayanor N, Yates RW. Dynamics of FSH-induced follicular growth in subfertile women: Relationship with age, insulin resistance, oocyte yield and anti-Mullerian hormone. Hum Reprod 2006;21:1436-41.
5. de Vet A, Laven JS, de Jong FH, Themmen AP, Fauser BC. Antimullerian hormone serum levels: A putative marker for ovarian aging. Fertil Steril 2002;77:357-62.
6. Seifer DB, Scott RT Jr, Bergh PA, Abrogast LK, Friedman CI, Mack CK, et al. Women with declining ovarian reserve may demonstrate a decrease in day 3 serum inhibin B before a rise in day 3 follicle-stimulating hormone. Fertil Steril 1999;72:63-5.
7. Nelson SM, Yates RW, Fleming R. Serum anti-Mullerian hormone and FSH: Prediction of live birth and extremes of response in stimulated cycles: Implications for individualization of therapy. Hum Reprod 2007;22:2414-21.
8. Sreeskandarajan S, Flowers MM, Karro JE, Liang C. A MATLAB-based tool for accurate detection of perfect overlapping and nested inverted repeats in DNA sequences. Bioinformatics 2013.
9. Kaatiala J, Yrttiaho S, Forssman L, Perdue K, Leppänen J. A graphical user interface for infant ERP analysis. Behav Res Methods 2013.
10. Pandian Z, McTavish AR, Aucott L, Hamilton MP, Bhattacharya S. Interventions for ‘poor responders’ to controlled ovarian hyperstimulation (COH) in in-vitro fertilisation (IVF). Cochrane Database Syst Rev 2010:CD004379.
11. Marci R, Graziano A, Lo Monte G, Marra E, et al. GnRH antagonists in assisted reproductive techniques: A review on the Italian experience. Eur Rev Med Pharmacol Sci 2013;17:853-73.
12. Baird DT, Collins J, Egozcue J, Evers LH, Gianaroli L, Leridon H, et al. ESHRE Capri Workshop Group. Fertility and ageing. Hum Reprod Update 2005;11:261-76.
13. Pal L, Santoro N. Age-related decline in fertility. Endocrinol Metab Clin North Am 2003;32:669-88.
14. van Rooij JA, Broekmans FJ, Hulswout CC, Scheffer GJ, Eijkmans MJ, de Jong FH, et al. Use of ovarian reserve tests for the prediction of ongoing pregnancy in couples with unexplained or mild male infertility. Reprod Biomed Online 2006;12:182-90.
15. Ehner T, Sommergubner M, Moser M, Shebl O, Schreier-Lechner E, Tews G. Basal level of anti-Mullerian hormone is associated with oocyte quality in stimulated cycles. Hum Reprod 2006;21:2022-6.
16. Verhagen TE, Hendriks DJ, Bancsi LF, Mol BW, Broekmans FJ. The accuracy of multivariate models predicting ovarian reserve and pregnancy after in vitro fertilization: A meta-analysis. Hum Reprod Update 2008;14:95-100.
17. Shen S, Khabani A, Klein N, Battaglia D. Statistical analysis of factors affecting fertilization rates and clinical outcome associated with intracytoplasmic sperm injection. Fertil Steril 2003;79:355-60.

Figure 1: Age and AMH relationship

Jeve: The combined use of anti-mullerian hormone and age factors particularly affecting subgroup of women labelled as reduced responders and analysed to get a user friendly predictive model.

This study evaluated the relationship between two important factors, age, and AMH, influencing outcome of assisted reproduction in reduced responder group. The relationship between age and AMH is shown in Figure 1. As figure shows the value of AMH is not same within same age group. Hence it is crucial to have both predictors taken into the consideration whilst predicting ovarian response. This figure illustrates the importance of having both predictors that is age and AMH calculated together to predict more accurate response. All previous studies analyzing predictive potential were done in normal, reduced, and high responders with many variables at same time. In present study, we analyzed combined predictive potential of AMH and age affecting outcomes. This study has relatively small population size and it is a major limitation. There is a need to focus on this particular group of women to improve outcome without adding any financial burden or emotional stress. This can be achieved only with good prediction of response and individualizing therapy accordingly. Current evidence favors antagonist approach to treat reduced responder group. Current evidence supports AMH and age as good predictors of ovarian response over any other single or multiple available predictors. We have tried to introduce new approach of combining both factors using a simple equation. We accept the limitation of having small number of study subjects to draw any conclusions based on this study alone. Hence, further studies are required to establish strong evidence before recommending combination of age and AMH prediction model and consequent individualized treatment strategy in practice.

Source of Support: Nil, Conflict of Interest: None declared.